Phenotap used to sound like the sort of health-tech company you could explain at brunch: wear a small sensor, watch your ketones move by the hour, learn what breakfast did to your metabolism. The New York startup’s early materials paired a non-invasive monitor called KetoTap with a personalized-nutrition idea called Cognizant Nutrition. It was a consumer story with a clean loop - measure, understand, adjust.
Four years after its 2021 founding, the company’s most consequential product was no longer the wearable. It was the molecule inside it. Phenotap now presents itself as a B2B supplier of KetoTap Core, a patent-pending beta-hydroxybutyrate, or BHB, oxidase. In plain English: it wants to sell device makers the enzyme that turns a ketone reading into an electrical signal. Its homepage delivers the business model in nine economical words: “We make the enzyme; our partners build the devices.”
The thing that failed first was the chemistry
There is no public postmortem in which Phenotap says its first product failed. The more useful failure sits upstream and predates the company: conventional ketone-sensing chemistry. Blood ketone strips typically rely on a BHB dehydrogenase reaction. That reaction needs an external NAD+ co-factor, a mediator and more complicated immobilization on the sensor. Every extra part adds cost and another way for performance to decay.
Glucose sensing got a friendlier engine. Glucose oxidase can convert its target directly into a clean electrochemical signal, which helped make cheap strips and long-wearing continuous glucose monitors possible. Phenotap argues that ketones never had an equivalent. Existing dehydrogenase systems can lose activity too quickly for the 10-to-14-day wear window manufacturers expect from a commercial continuous monitor.
Glucose has an oxidase. Ketones never have.Phenotap’s summary of the market gap
That reframes the category. The missing product is not primarily another dashboard, patch or lifestyle recommendation. It is a stable enzyme. Working with the Siegel Lab at UC Davis, the UC San Diego Center for Wearable Sensors, Codexis and EvoEnzyme, Phenotap says it engineered a BHB oxidase that requires neither external NAD+ nor a mediator. The company describes standard immobilization and electrochemistry compatible with processes already used for glucose devices.
A $3 million job, with unusually specific instructions
The cost we can see is $3 million. In March 2025, the Leona M. and Harry B. Helmsley Charitable Trust made an 18-month program-related investment in Phenotap, structured as a loan. It was publicly announced that July. This was not a generic seed round for hiring growth marketers and ordering hoodies. The stated project was development of a BHB oxidase to enable continuous ketone sensing, particularly for people with type 1 diabetes.
That medical use case gives the technology weight beyond the wellness aisle. Diabetic ketoacidosis, or DKA, can develop when insulin is insufficient and ketones rise to dangerous levels. Glucose is continuously visible to many patients; ketones are usually checked episodically with blood or urine tests. A combined glucose-ketone sensor could warn about a deteriorating situation earlier. Helmsley has explicitly backed that possibility.
But the money also reveals what remains unfinished. In 2025, the investment was meant to make the proprietary enzyme active and stable enough for ketone-sensing devices. Phenotap now calls KetoTap Core commercially ready and says production scaling and customer sampling are beginning in the second quarter of 2026. “Ready to sample” is a meaningful milestone. It is not the same as a cleared device, a high-volume supply contract or a sensor on somebody’s arm.
Own the experience
A non-invasive sensor, hourly ketone trends on a smart device and personalized nutrition feedback for consumers.
Own the bottleneck
A BHB oxidase supplied to manufacturers of strips, meters and continuous or dual-analyte monitors.
What changed their mind?
Phenotap has not published a tidy pivot memo, so motive should not be reverse-engineered into fact. The public record does show a change in emphasis. A 2024 UC Davis description called KetoTap the world’s first non-invasive continuous ketone monitor and promised hourly readings to a smartphone. A 2025 university startup packet still placed the company at proof-of-concept and core-IP stage. The current company site leads with KetoTap Core and names device manufacturers as customers.
The logic is persuasive. Building a finished medical wearable asks a five-person startup to solve enzyme chemistry, sensor engineering, hardware, firmware, software, clinical evidence, regulation, manufacturing, reimbursement and consumer acquisition. Supplying one critical component does not erase those burdens, but it reallocates many of them to companies that already know how to build glucose strips and CGMs.
The change also alters who writes the check. Early Phenotap materials spoke to keto dieters, fasters and fitness enthusiasts. Current materials speak to blood-meter manufacturers and teams building continuous or combined glucose-ketone monitors. The end user may still be a patient, clinician or metabolism-curious consumer. The direct buyer is an OEM with a validation plan and a production line.
The OEM chain
The moat is a drop-in, if it really drops in
Phenotap’s differentiation is not that it measures ketones. Finger-prick meters already do that, breath devices estimate aspects of ketosis, and several companies are pursuing continuous biomarkers. The claim is architectural: KetoTap Core behaves more like the oxidase chemistry the glucose industry already understands. No external co-factor. No mediator. A degradation profile the company says is comparable to glucose oxidase. Familiar immobilization. Patent-pending composition-of-matter protection.
If those claims survive customer validation, the product could lower unit costs for ketone strips, extend shelf life and make longer-wearing continuous sensors more practical. It could also fit a combined CGM-CKM roadmap without forcing manufacturers to invent an entirely foreign process. That is the “drop-in” promise - not effortless adoption, but fewer new things to learn at once.
The market position is picks and shovels for metabolic sensing. Consumer brands such as Levels, Lumen and Biosense sell insight or devices around metabolism. Large medtech companies own manufacturing, distribution and regulatory machinery. Phenotap wants the narrow middle: proprietary biochemistry that can travel through someone else’s machinery.
What it charges for that journey is not public. The likely menu could include enzyme supply, licensing or development support, but Phenotap has disclosed none of those terms and no commercial customer names. That silence matters. An OEM model trades the noisy mathematics of consumer subscriptions for a smaller number of slower, larger decisions. A manufacturer will care less about a beautiful app than lot-to-lot consistency, storage life, reproducible sensor response and supply assurance. The sales proof is therefore not a waitlist. It is technical data that survives another company’s lab. If Phenotap clears that bar, one design win could put KetoTap Core into a family of strips or sensors. If it does not, there is no consumer brand strong enough to rescue the chemistry.
What founders can copy
Shrink the product until the bottleneck is visible.
- Map every dependency between the customer’s desire and the promised outcome.
- Find the component that makes the rest too costly, unstable or slow.
- Design around infrastructure buyers already own.
- Let partners carry the layers where they have an unfair advantage.
The stealable idea is not “pivot to biotech.” It is to identify which layer creates the category’s recurring pain, then ask whether owning that layer produces a better company than owning the whole stack. Phenotap’s original vision required consumers to trust a new brand and manufacturers to be built from scratch. Its present vision asks established manufacturers to swap in a better engine. One sale can travel farther, although it will probably travel slower.
When the playbook does not work
A component strategy fails if the component is merely interesting rather than indispensable. KetoTap Core must retain activity and stability under real storage, manufacturing and wear conditions. It must produce useful signal across relevant BHB ranges. It must integrate without creating fresh interference, calibration or biocompatibility problems. And it must be economical at scale.
The approach also weakens when buyers insist on owning the enzyme, when an incumbent develops comparable chemistry, or when the ketone market is too small to justify another analyte on a sensor. Medical adoption will depend on clinical evidence and regulatory clearance of finished devices that Phenotap does not control. Wellness adoption is easier to imagine but harder to defend if readings do not change behavior.
Culture matters here because almost none of this can be done alone. Phenotap’s visible team spans commercial strategy, biosensing science and technology infrastructure. Its extended bench includes UC Davis protein designers, UC San Diego sensor researchers, directed-evolution specialists at Codexis and EvoEnzyme, and venture-building support from Cornucopian Capital’s Barnstorm Foundry. For a small company, partnership is not decoration. It is the operating system.
Phenotap’s next proof will be deliberately boring: samples, data, manufacturing conversations and eventually a customer willing to put the enzyme into a regulated product. That is less photogenic than a wearable mockup. It is also where the company’s sharper thesis gets tested. The ketone revolution, if it arrives, may begin with a tiny vial shipped to somebody else’s factory.